Parul Agarwal, MD

Agarwal P, Guo M, Munjal K, Qi H, Parkinson R, Ferguson A, Mitchell C, Harrison J, Anders RA, Thompson ED, Wang H, De Jesus A, Zheng L, He J, Burkhart R, Narang A, George B, Jaffee EM, Yarchoan M, Laheru D, Osipov A. A phase II study of neoadjuvant GVAX and cyclophosphamide combined with nivolumab and SBRT followed by surgery in borderline resectable pancreatic adenocarcinoma , Clin Cancer Res: 2025

Mohindroo C, Baydogan S, Agarwal P, Wright RD, Prakash LR, Mork ME, Klein AP, Laheru DA, Maxwell JE, Katz MHG, Dasari A, Kim MP, He J, McAllister F, De Jesus-Acosta A. Germline Testing Identifies Pathogenic/Likely Pathogenic Variants in Patients with Pancreatic Neuroendocrine Tumors , Cancer Prevention Research, 17(7): 2024,335-342

Wilbur HC, Le DT, Agarwal P. Immunotherapy of MSI Cancer: Facts and Hopes , Clin Cancer Res, 30(8): 2024,1438-1447

Lau-Min KS, Marini J, Shah NK, Pucci D, Blauch AN, Cambareri C, Mooney B, Agarwal P, Johnston C, Schumacher RP, White K, Gabriel PE, Rosin R, Jacobs LA, Shulman LN. Pilot Study of a Mobile Phone Chatbot for Medication Adherence and Toxicity Management Among Patients With GI Cancers on Capecitabine , JCO Oncol Pract: 2024

Chen SY, Heumann TR, Agarwal P, Zheng L. The clinical application of immuno-therapeutics , Clinical Immuno-Oncology: 2024,237-288

Mohindroo C, Baydogan S, Agarwal P, Laheru D, Wright R, Prakash L, Mork ME, Klein ME, Maxwell J, Katz MHG, Dasari A, Kim MP, He J, McAllister F, De Jesus-Acosta A. Prevalence of germline variants in patients with pancreatic neuroendocrine tumors. , Journal of Clinical Oncology, The American Society of Clinical Oncology Annual Meeting, Chicago IL., 41: 2023

Agarwal P, Qi H, Munjal K, Gai J, Ferguson A, Parkinson R, Harrison J, Rodriguez C, Anders RA, Thompson ED, Burkhart R, He J, Narang A, De Jesus-Acosta A, Zheng L, Jaffee EM, George B, Laheru DA, Yarchoan M, Osipov A. Overall survival (OS) and pathologic response rate from a phase II clinical trial of neoadjuvant GVAX pancreas vaccine (with cyclophosphamide) in combination with nivolumab and stereotactic body radiation therapy (SBRT) followed by definitive resection for patients with borderline resectable pancreatic adenocarcinoma (BR-PDAC). , Journal of Clinical Oncology, The American Society of Clinical Oncology Annual Meeting, Chicago IL., 41: 2023

Chapin WJ, Agarwal P, DiCicco L, Palmer R, Cenou N, Chi Huang AC, Karasic TB. Phase II trial of XmAb20717 (vudalimab) in patients with advanced biliary tract cancers. , Journal of Clinical Oncology, The American Society of Clinical Oncology Annual Meeting, Chicago IL., 41(16): 2023

Luke J, Sanborn RE, Rodón J, Patel M, Agarwal P, Friedman E, Peterson C, Kelley H, Wright E, Danaee H, Sun H, Barth C, Reilly T, Redig AJ, Friedman C. Phase 1/2 study of HST-1011, an oral CBL-B inhibitor, alone and in combination with anti-PD1 in patients with advanced solid tumors , Cancer Res. American Association for Cancer Research Annual Meeting, Orlando, FL., 83(8): 2023

Christenson ES, Lim SJ, Durham J, De Jesus-Acosta A, Bever K, Laheru D, Ryan A, Agarwal P, Scharpf RB, Le DT, Wang H. Cell-free DNA Predicts Prolonged Response to Multi-agent Chemotherapy in Pancreatic Ductal Adenocarcinoma , Cancer Res Commun, 2(11): 2022,1418-1425